MatchMedi
한국어

Options mapped

Lung cancer: options by country

Sourced options by country plus visit-prep questions for lung cancer — subtype, stage, biomarkers, and clinical-trial timing.

Options mappedSolid tumorLast checked May 2026

Options by country

Treatments by country

Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.

Non-small cell lung cancer

United States

  • lazertinib (Lazcluze) + amivantamab-vmjw (Rybrevant)[1]FDA-approvedfirst-line, locally advanced or metastatic, EGFR exon 19 deletion or exon 21 L858R substitution (detected by an FDA-approved test) · MARIPOSA enrolled patients with no prior systemic therapy for advanced disease; FDA approval summary notes a venous thromboembolic-event safety signal / prophylactic anticoagulation language.

European Union

  • lazertinib (Lazcluze) + amivantamab (Rybrevant)[2]EMA: authorised in the EUfirst-line, advanced, EGFR exon 19 deletion or exon 21 L858R substitution, adults · Used in combination with amivantamab (Rybrevant EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant). EMA notes EGFR testing required before treatment and anticoagulation at initiation for VTE risk. Member-state reimbursement not verified.
  • lorlatinib (Lorviqua)[3]EMA: authorised in the EUadvanced, ALK-positive, adults; used on its own when not previously treated with an ALK tyrosine kinase inhibitor · Prescription-only; treatment started and supervised by a doctor experienced in cancer medicines. Member-state reimbursement not verified.

United Kingdom

  • amivantamab (Rybrevant) + lazertinib (Lazcluze)[4]NICE-recommended on the NHS (England and Wales), within marketing authorisationuntreated advanced, EGFR exon 19 deletion or exon 21 L858R substitution, adults · Recommended only if the companies provide the drugs according to the commercial arrangements; framed against usual osimertinib-based regimens.
  • lorlatinib (Lorviqua)[5]NICE-recommended on the NHS (England and Wales)advanced, ALK-positive, adults who have not had an ALK inhibitor · Citation updated from the now-superseded TA909 to the current NICE TA1103 (published 21 October 2025), which replaced it and carries the same recommendation for this indication. Recommended only if the company provides it according to the commercial arrangement; NHS England/Wales context, not a universal UK availability statement.
  • selpercatinib (Retsevmo)[6]NICE-recommended on the NHS (England and Wales)advanced, RET fusion-positive, previously treated but not with a RET inhibitor · TA1042 covers previously treated disease; untreated RET fusion-positive advanced NSCLC is addressed via a separate managed-access recommendation under NICE TA911 (https://www.nice.org.uk/guidance/ta911). Recommendation does not cover everyone licensed for selpercatinib.

Japan

  • lorlatinib (Lorbrena)[7]PMDA-approved (Japan)ALK fusion gene-positive unresectable advanced and/or recurrent non-small cell lung cancer · PMDA review report states the approved indication; reimbursement and formulary status not verified.

Small cell lung cancer

United States

  • durvalumab (Imfinzi)[8]FDA-approvedlimited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy
  • atezolizumab (Tecentriq) + carboplatin + etoposide[9]FDA-approvedfirst-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) · Approved in combination with carboplatin and etoposide.
  • tarlatamab-dlle (Imdelltra)[10]FDA-approved (traditional approval)adults with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy · Prescribing information includes warnings for cytokine release syndrome and neurologic toxicity (ICANS).

European Union

  • durvalumab (Imfinzi)[11]EMA-authorised (central marketing authorisation)untreated extensive-stage SCLC (with chemotherapy) and untreated limited-stage SCLC not worsened after platinum-based chemoradiation, adults · Central EU authorisation only; member-state reimbursement not verified. The EPAR also covers NSCLC and other indications.

United Kingdom

  • tarlatamab (Imdelltra)[12]NICE: not recommended for routine use on the NHS (England)extensive-stage small cell lung cancer after 2 or more prior treatments including platinum-based chemotherapy, adults · NICE states tarlatamab is not required to be funded and should not be used routinely in the NHS in England for this indication; this is an NHS funding decision, not a statement about regulatory licensing or clinical-trial access.

Japan

  • durvalumab (Imfinzi) + platinum + etoposide[13]PMDA-approved (Japan)extensive-stage small cell lung cancer · PMDA review report; used in combination with platinum-based chemotherapy and etoposide. Reimbursement and formulary status not verified.
  • atezolizumab (Tecentriq) + carboplatin + etoposide[14]PMDA-approved (Japan)extensive-stage small cell lung cancer · PMDA indications document lists extensive-stage SCLC; used with carboplatin and etoposide. Reimbursement and formulary status not verified.
  • tarlatamab (Imdelltra)[15]PMDA-approved (Japan)small cell lung cancer that has progressed after cancer chemotherapy · PMDA safety document (Japanese market launch listed April 2025); monitoring for cytokine release syndrome applies. Reimbursement and formulary status not verified.

Lung cancer

United States

  • combination chemotherapy alone when thoracic radiation therapy is contraindicated[16]NCI PDQ: standard optionno molecular biomarker gating stated; treatment choice is shaped by radiation suitability and emergency presentation; limited-stage SCLC when thoracic radiation is contraindicated, or urgent presentation such as superior vena cava syndrome. · This is a pathway exception context, not the preferred standard for otherwise fit limited-stage patients. The fetched source does not define every contraindication to thoracic radiation or the exact emergency-treatment sequencing for an individual case. Confidence/conflicts: High for the PDQ chemotherapy-alone exception and superior-vena-cava-syndrome emergency-treatment framing. No source conflict identified in this cycle.
  • durvalumab (Imfinzi) + etoposide + carboplatin or cisplatin[17]FDA-approvedfirst-line adult extensive-stage SCLC. · Direct FDA source for the 2020 ES-SCLC approval was not opened this cycle; ASCO and AstraZeneca pages cite the FDA approval. FDA primary-source confirmation remains a gap for this specific cell. Confidence/conflicts: medium-high; no conflict identified. FDA primary page should be fetched in a later pass.
  • durvalumab (Imfinzi) + etoposide + carboplatin or cisplatin[18]Standard option (per U.S. Food and Drug Administration)first-line previously untreated extensive-stage disease. · This FDA notice confirms the U.S. first-line regimen but does not address payer restrictions, later-line reuse, or hospital formulary logistics. Confidence/conflicts: High for the exact FDA first-line ES-SCLC approval scope. No conflicting primary U.S. source was reviewed in this cycle.
  • endobronchial laser therapy, brachytherapy, expandable metal stents, or salvage external-beam radiation therapy[16]NCI PDQ: standard optionno molecular biomarker gating stated; the selector is symptom-producing local thoracic recurrence or airway obstruction after prior chemotherapy; recurrent SCLC after initial chemotherapy when the immediate problem is malignant airway obstruction or progressive intrathoracic symptoms needing local palliation. · This is a palliative local-control finding, not a disease-modifying systemic approval. The same PDQ section notes that only rare patients achieve long-term survival after salvage radiation in this context. Confidence/conflicts: High for the PDQ palliative-pathway statements covering airway-intervention options and salvage thoracic radiation after chemotherapy failure. No conflicting primary U.S. source was reviewed in this cycle.
  • lorlatinib (Lorbrena)[19]FDA-approvedALK-positive, detected by an FDA-approved test; metastatic ALK-positive NSCLC; FDA page describes a trial in patients who had not received prior systemic therapy for metastatic disease. · FDA also approved the VENTANA ALK (D5F3) CDx Assay as companion diagnostic for lorlatinib. The approval page distinguishes the 2021 regular approval from the earlier accelerated approval for later-line use.
  • lurbinectedin (Zepzelca)[16]NCI PDQ: standard optionno molecular biomarker gating stated; recurrence timing and prior treatment response shape systemic choice rather than a named mutation; recurrent SCLC after first-line therapy, including second-line treatment planning. · This finding records PDQ’s current recurrent-SCLC option listing, not a full label-specific eligibility statement. The same PDQ section stresses that second-line responses are generally limited in duration and that trial participation remains appropriate. Confidence/conflicts: High for the PDQ inclusion of lurbinectedin as a recurrent-SCLC chemotherapy option. No conflicting primary U.S. source was reviewed in this cycle.
  • lurbinectedin (Zepzelca) + atezolizumab (Tecentriq)[20]FDA-approvedno molecular biomarker gating stated; eligibility depends on disease not progressing after the specified first-line induction regimen; maintenance treatment after first-line atezolizumab-carboplatin-etoposide induction without progression. · This is a maintenance indication tied to a specific induction backbone and non-progression requirement. The FDA notice also points to lurbinectedin warnings for myelosuppression, hepatotoxicity, extravasation tissue necrosis, rhabdomyolysis, and embryo-fetal toxicity. Confidence/conflicts: High for the U.S. maintenance approval date, indication scope, induction-backbone requirement, and safety-warning framing from the FDA notice. No conflicting primary U.S. source was reviewed in this cycle.
  • lurbinectedin (Zepzelca) + atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza)[20]Standard option (per U.S. Food and Drug Administration)no molecular biomarker gating stated; eligibility depends on disease not progressing after the specified first-line induction regimen; maintenance treatment after first-line subcutaneous atezolizumab-hyaluronidase-carboplatin-etoposide induction without progression. · This finding is route-specific and applies to the subcutaneous atezolizumab-hyaluronidase formulation named in the approval. The FDA notice states the recommended maintenance dosage for atezolizumab and hyaluronidase-tqjs is administered every 3 weeks until progression or unacceptable toxicity. Confidence/conflicts: High for the distinct U.S. approval scope covering the subcutaneous atezolizumab-hyaluronidase formulation in ES-SCLC maintenance. No conflicting primary U.S. source was reviewed in this cycle.
  • prophylactic cranial irradiation (PCI), standard dose 25 Gy in 10 fractions[16]NCI PDQ: standard optionresponse-based selection; no molecular biomarker gating stated; post-response CNS-relapse-risk reduction after complete remission in limited-stage SCLC. · This finding captures PDQ’s remission-based PCI framing and standard-dose reference, not individualized neurocognitive-risk decision-making. The source does not imply PCI is mandatory for every patient in remission. Confidence/conflicts: High for the PDQ PCI indication framing, CNS-risk reduction statement, and standard-dose 25 Gy in 10 fractions reference. No source conflict identified in this cycle.
  • radiation therapy, including whole-brain radiation therapy for brain metastases[16]NCI PDQ: standard optionno molecular biomarker gating stated; the selector is metastatic-site symptom burden and whether chemotherapy is likely to palliate promptly; extensive-stage SCLC with symptomatic metastatic disease needing local palliation in addition to or ahead of systemic chemotherapy effect. · This is PDQ pathway guidance rather than a branded label. The finding is about local palliation and site-directed control, not about replacing systemic therapy for extensive-stage disease. Confidence/conflicts: High for the PDQ description of palliative radiation as a standard option for extensive-stage SCLC metastatic sites and for whole-brain radiation therapy in brain metastases. No conflicting primary U.S. source was reviewed in this cycle.
  • selpercatinib (Retevmo)[21]FDA-approvedRET fusion-positive, detected by an FDA-approved test; locally advanced or metastatic RET fusion-positive NSCLC. · FDA page states selpercatinib had previously received accelerated approval for the NSCLC indication in 2020 and was converted to regular approval in 2022 based on additional LIBRETTO-001 data.
  • surgical resection followed by adjuvant chemotherapy with or without radiation therapy[16]NCI PDQ: standard optionno molecular biomarker gating stated; small tumor extent and nodal confinement define the surgical subset; minority of patients with very limited limited-stage SCLC in a resection-eligible setting. · The PDQ explicitly says the role of surgery is unproven and should be considered case by case because randomized trials have not demonstrated an overall-survival benefit when surgery is added to chemoradiation. This is not a routine SCLC surgery recommendation for most patients. Confidence/conflicts: High for the PDQ description of surgery as a minority very-limited-stage option with adjuvant-therapy context and lack of randomized-survival proof. No source conflict identified in this cycle.
  • thoracic radiation therapy[16]NCI PDQ: standard optionno molecular biomarker gating stated; the selector is response after initial chemotherapy; post-chemotherapy consolidative thoracic-radiation consideration for extensive-stage SCLC that has responded to systemic treatment. · PDQ summarizes this as an available option after response, not a universal requirement for every responding patient. The cited trial data in PDQ show improved intrathoracic control and secondary survival signals, but the page still frames this as a response-dependent radiation decision. Confidence/conflicts: High for the PDQ statement that chemotherapy-responsive extensive-stage SCLC patients may receive thoracic radiation therapy. No conflicting primary U.S. source was reviewed in this cycle.
  • topotecan (generic; Hycamtin)[16]NCI PDQ: standard optionno molecular biomarker gating stated; recurrence timing and prior treatment response shape systemic choice rather than a named mutation; recurrent SCLC after first-line therapy, including second-line treatment planning. · This is PDQ pathway guidance rather than a label extract, and it does not specify which recurrence subgroups should preferentially receive topotecan over other options. The same PDQ section notes that benefit depends on whether relapse is sensitive or resistant and that responses after second-line therapy are usually short-lived. Confidence/conflicts: High for the PDQ statement that topotecan is a standard chemotherapy option for recurrent SCLC. No conflicting primary U.S. source was reviewed in this cycle.
  • topotecan and lurbinectedin (Zepzelca) as recurrent-disease systemic options[16]NCI PDQ: standard optionno molecular biomarker gating stated; recurrence timing and chemosensitivity shape option selection; recurrent SCLC after first-line therapy, including second-line treatment planning. · This finding groups two recurrent-disease systemic options from the same PDQ section and does not provide label-level eligibility or dosing. The page also stresses that benefit depends on whether relapse is sensitive or resistant, with generally limited survival after second-line therapy. Confidence/conflicts: High for the PDQ recurrent-SCLC option list naming topotecan as a standard chemotherapy and lurbinectedin as another option. No source conflict identified in this cycle.
  • trilaciclib (Cosela)[22]Standard option (per U.S. Food and Drug Administration)no molecular biomarker gating stated; eligibility depends on receiving a platinum-etoposide-containing chemotherapy regimen for ES-SCLC; supportive-care use before platinum-etoposide-containing chemotherapy for ES-SCLC. · This is a supportive-care indication rather than an antitumor treatment approval. The label states COSELA is given as a 30-minute intravenous infusion completed within 4 hours before chemotherapy on each treatment day. Confidence/conflicts: High for the exact FDA label indication covering prechemotherapy myeloprotection before platinum-etoposide-containing ES-SCLC treatment. No conflicting primary U.S. source was reviewed in this cycle.

European Union

  • durvalumab (Imfinzi)[23]Standard option (per European Medicines Agency)post-platinum-based chemoradiation, no-progression limited-stage adult disease. · This confirms current EU central-authorisation wording only. It does not establish member-state reimbursement or local post-chemoradiation sequencing rules. Confidence/conflicts: High for the exact current SmPC indication wording. This batch was run specifically to replace the earlier HTML-page consistency caveat with the downloadable product information.
  • durvalumab (Imfinzi)[23]Standard option (per European Medicines Agency)none stated; LS-SCLC post-chemoradiation and ES-SCLC first-line adult disease. · This is a careful inference from the structure of the current SmPC, not a standalone sentence saying that biomarker testing is unnecessary. Keep it framed as a document-based no-biomarker-prerequisite read, not as a broader biologic claim. Confidence/conflicts: Moderate-high. The source directly shows explicit biomarker-testing language for some Imfinzi indications and none for SCLC, but this cell remains an inference from document structure rather than a quoted affirmative statement.
  • durvalumab (Imfinzi) + etoposide + carboplatin or cisplatin[23]Standard option (per European Medicines Agency)first-line extensive-stage adult disease. · This confirms central-authorisation status only. It does not establish country-specific reimbursement, formulary availability, or later-line reuse. Confidence/conflicts: High for the exact current SmPC first-line ES-SCLC indication wording. No conflicting primary EU source was reviewed in this cycle.
  • durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin[11]Standard option (per European Medicines Agency)no molecular biomarker gating stated; the selector is previously untreated extensive-stage disease; first-line treatment for untreated extensive-stage SCLC in the European Union. · This verifies EU central authorisation status, not member-state reimbursement or practical access in any specific EU country. Confidence/conflicts: High for EU central-authorisation status of first-line ES-SCLC from the current EMA product-details section. No conflicting primary EU source was reviewed in this cycle.
  • tarlatamab (Imdylltra)[24]EMA authorisedDLL3-targeting bispecific; no biomarker test requirement stated in fetched EMA/EC sources; ES-SCLC after relapse/progression during or after platinum-based chemotherapy. · EMA states pricing and reimbursement decisions occur at member-state level after marketing authorisation. Amgen release is a company source for the EC decision; EMA product page should be fetched in a later pass when available. Confidence/conflicts: medium-high; EMA confirms positive CHMP opinion and Amgen reports EC authorisation. EMA EPAR/EC decision page remains preferred follow-up source.
  • tislelizumab (Tevimbra) + etoposide + platinum chemotherapy[25]Standard option (per European Medicines Agency)no molecular biomarker gating stated in the fetched EMA SCLC indication text; first-line treatment for adult extensive-stage SCLC. · This verifies EU central authorisation status only. It does not establish reimbursement, hospital formulary uptake, or routine availability in any specific EU member state. Confidence/conflicts: High for EU central-authorisation status of first-line ES-SCLC from the current EMA product-details section. No conflicting primary EU source was reviewed in this cycle.
  • tislelizumab (Tevimbra) + platinum-based chemotherapy + etoposide[25]Standard option (per European Medicines Agency)no molecular biomarker gating stated in the fetched EMA SCLC study summary; first-line untreated extensive-stage SCLC. · This is an EMA efficacy-summary finding, not a separate reimbursement or comparative-effectiveness decision by any member state. Confidence/conflicts: High for the EMA overview efficacy summary reporting 15.5-month versus 13.5-month overall survival in untreated ES-SCLC. No conflicting primary EU source was reviewed in this cycle.

United Kingdom

  • Tarlatamab (Imdylltra)[26]NICE recommendedES-SCLC after two or more prior lines of treatment including platinum-based chemotherapy. · This is a negative NHS England routine-funding recommendation, not a statement about private access, clinical trials, or other UK nations. NICE records marketing-authorisation indication separately from its funding recommendation. Confidence/conflicts: High for NICE recommendation; conflict/contrast with U.S. FDA approval and EU authorisation context is jurisdictional, not evidentiary.
  • amivantamab (Rybrevant) + lazertinib (Lazcluze)[27]ApprovedEGFR exon 19 deletion or exon 21 L858R substitution mutation; untreated advanced NSCLC. · NICE frames this against usual treatments including osimertinib-based regimens and makes the recommendation conditional on commercial arrangements.
  • atezolizumab with carboplatin and etoposide[28]NICE recommendedno molecular biomarker gating stated; NICE recommendation is limited by ECOG performance status 0 or 1; first-line treatment for untreated extensive-stage SCLC in adults meeting the NICE ECOG requirement. · This is an England NICE reimbursement recommendation, not a whole-UK drug-label statement. The finding should not be generalized to patients outside the stated ECOG range. Confidence/conflicts: High for the England NICE recommendation scope, untreated ES-SCLC setting, and ECOG 0 to 1 restriction. No conflicting primary U.K. source was reviewed in this cycle.
  • chemoradiotherapy, meaning chemotherapy together with radiotherapy[29]Standard option (per Cancer Research UK)no molecular biomarker gating stated; treatment selection is stage- and fitness-based; initial treatment for limited-stage SCLC in people fit enough for combined-modality therapy. · This is a U.K. treatment-information page rather than a brand-specific commissioning or label source. The page does not specify the exact chemotherapy regimen or radiotherapy schedule within this finding. Confidence/conflicts: High for the U.K. statement that combined chemotherapy and radiotherapy is the main treatment for limited-stage SCLC. No conflicting U.K. source was reviewed in this cycle.
  • chemotherapy followed by radiotherapy[29]Standard option (per Cancer Research UK)no molecular biomarker gating stated; fitness for concurrent treatment is the relevant selector; limited-stage SCLC when the person is not fit enough for combined concurrent chemoradiotherapy. · The page gives a broad sequencing option and does not define a formal U.K. fitness threshold or specific sequential regimen. This should not be read as equivalent to the preferred concurrent approach when that is feasible. Confidence/conflicts: High for the U.K. sequential chemotherapy-then-radiotherapy fallback statement in limited-stage SCLC. No conflicting U.K. source was reviewed in this cycle.
  • chemotherapy, either alone or combined with radiotherapy or immunotherapy[30]Standard option (per NHS)no molecular biomarker gating stated; treatment choice is framed by stage and clinical condition rather than a named mutation; general U.K. SCLC treatment-pathway framing across cases where systemic therapy is being planned. · The NHS page is a broad treatment overview and does not assign specific regimens, commissioning rules, or stage-by-stage sequencing within this finding. Confidence/conflicts: High for the NHS statement that SCLC is usually treated with chemotherapy alone or combined with radiotherapy or immunotherapy. No conflicting primary U.K. source was reviewed in this cycle.
  • cyclical chemotherapy, with most people needing 4 to 6 cycles over 3 to 6 months[30]Standard option (per NHS)no molecular biomarker gating stated; chemotherapy-course planning depends on cancer type and grade rather than a named mutation in the fetched page; NHS chemotherapy-delivery planning when chemotherapy is being used for lung cancer including SCLC contexts. · This scheduling language is from a broad lung-cancer chemotherapy section rather than an SCLC-specific protocol. It should not be mistaken for a fixed regimen rule for every SCLC case. Confidence/conflicts: Moderate to high for the NHS description of how lung-cancer chemotherapy is commonly delivered in cycles and over multi-month courses. The scope caveat is important because the page is not an SCLC-specific regimen protocol.
  • durvalumab (Imfinzi)[31]Standard option (per electronic medicines compendium / AstraZeneca UK Limited)no molecular biomarker gating stated; the selector is disease that has not progressed after platinum-based chemoradiation therapy; post-chemoradiation monotherapy for adults with limited-stage SCLC without progression after platinum-based chemoradiation. · This verifies current U.K. label status only. It does not by itself establish England-specific NICE funding, NHS commissioning, or local formulary uptake. Confidence/conflicts: High for the exact current U.K. SmPC indication text for LS-SCLC after platinum-based chemoradiation without progression. No conflicting primary U.K. label source was reviewed in this cycle.
  • durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin, followed by durvalumab monotherapy[31]Standard option (per electronic medicines compendium / AstraZeneca UK Limited)no molecular biomarker gating stated; the selector is previously untreated extensive-stage disease; first-line treatment for untreated extensive-stage SCLC, using durvalumab with platinum-etoposide induction followed by durvalumab maintenance monotherapy. · This verifies current labelled regimen structure in the U.K. SmPC. It does not confirm a NICE appraisal, NHS England commissioning status, or actual center-level availability. Confidence/conflicts: High for the U.K. SmPC statement covering first-line ES-SCLC and for the linked dosing table showing induction followed by durvalumab monotherapy. No conflicting primary U.K. label source was reviewed in this cycle.
  • immunotherapy after chemoradiotherapy[29]Standard option (per Cancer Research UK)no molecular biomarker gating stated; post-treatment disease-control status and general fitness are the relevant selectors; post-chemoradiotherapy limited-stage SCLC when the cancer has not grown and the person is fit enough for further treatment. · The page does not name a specific immunotherapy medicine, funding route, or appraisal. This verifies the broad U.K. post-chemoradiotherapy immunotherapy pathway concept only, not the exact branded access statement for durvalumab. Confidence/conflicts: High for the broad U.K. statement that some people receive immunotherapy after chemoradiotherapy if the cancer has not grown and fitness is adequate. Exact branded NHS commissioning remains unverified in this cycle.
  • lorlatinib (Lorviqua)[32]NICE recommendedALK-positive; untreated with prior ALK inhibitor; advanced ALK-positive NSCLC in adults. · NICE recommendation is tied to the commercial arrangement and should not be generalized outside the NICE-covered NHS context without local verification.
  • prophylactic cranial irradiation (PCI)[30]Standard option (per NHS)no molecular biomarker gating stated; selection is based on brain-metastasis risk within the SCLC pathway; brain-metastasis-risk reduction during SCLC treatment. · The fetched NHS page gives a broad PCI description and does not specify remission criteria, dose schedule, or neurocognitive tradeoff discussions in this finding. Confidence/conflicts: High for the NHS confirmation that PCI is sometimes used during SCLC treatment as a preventative whole-brain radiation measure. No conflicting primary U.K. source was reviewed in this cycle.
  • regular MRI brain surveillance instead of prophylactic cranial irradiation (PCI)[29]Standard option (per Cancer Research UK)no molecular biomarker gating stated; the selector is post-treatment brain-surveillance planning after disease control; post-treatment limited-stage SCLC after the lung cancer has stopped growing, when the team is choosing brain-risk management between PCI and MRI surveillance. · This page frames MRI surveillance as an alternative monitoring pathway and does not define a detailed scan interval. The best option is explicitly described as something the healthcare team discusses with the patient. Confidence/conflicts: High for the U.K. MRI-surveillance-instead-of-PCI statement after treatment. No conflicting U.K. source was reviewed in this cycle.
  • selpercatinib (Retsevmo)[33]NICE recommendedRET fusion-positive; previously treated RET fusion-positive advanced NSCLC not previously treated with a RET inhibitor; separate managed-access route for untreated advanced disease. · Recommendation scope does not include everyone licensed for selpercatinib; TA1042 evaluates previously treated disease and references managed access for untreated disease under TA911.
  • surgery with postoperative chemotherapy or radiotherapy[30]Standard option (per NHS)no molecular biomarker gating stated; the key selector is unusually early-stage disease; very early-stage SCLC where surgery is exceptionally being considered. · This is an exception-pathway finding. The NHS source explicitly frames surgery as uncommon in SCLC and does not define a formal surgical eligibility checklist. Confidence/conflicts: High for the NHS framing that surgery is uncommon in SCLC but may be used very early, with adjuvant chemotherapy or radiotherapy possible afterward. No conflicting primary U.K. source was reviewed in this cycle.

Japan

  • durvalumab (Imfinzi) + platinum agent + etoposide[13]PMDA-approved (Japan)extensive-stage SCLC; AstraZeneca page describes first-line treatment, and PMDA review describes chemotherapy-naive ES-SCLC CASPIAN development. · PMDA report includes an approval condition requiring development and appropriate implementation of a risk management plan and notes further investigation of febrile neutropenia via post-marketing surveillance. Confidence/conflicts: high for Japanese approval and indication scope; no source conflict identified. Reimbursement was not assessed.
  • lazertinib mesilate hydrate (Lazcluze) + amivantamab (Rybrevant)[34]PMDA-approved (Japan)EGFR mutation-positive; unresectable advanced or recurrent EGFR mutation-positive NSCLC. · PMDA list and update confirm Japanese approval/indication scope but do not by themselves establish reimbursement status, sequencing, or individual eligibility. A PMDA precautions document notes renal-impairment considerations for the concomitant amivantamab/lazertinib use context. Confidence/conflicts: high for approval and Japanese indication class; no source conflict identified. Reimbursement not assessed.
  • lorlatinib (Lorbrena)[34]PMDA-approved (Japan)ALK fusion gene-positive; initially ALK TKI-resistant/intolerant unresectable advanced/recurrent disease; later indication change for unresectable advanced/recurrent ALK fusion gene-positive NSCLC. · PMDA review report required risk-management and post-marketing use-results survey conditions because Japanese clinical-study data were limited. The source does not establish reimbursement or individual eligibility. Confidence/conflicts: high for PMDA approval-list and review-report claims; no source conflict identified. Reimbursement not assessed.
  • selpercatinib (Retevmo)[34]PMDA-approved (Japan)RET fusion gene-positive; RET fusion gene-positive unresectable advanced or recurrent NSCLC. · PMDA list records approval and indication but does not establish reimbursement, line sequencing, or patient-specific eligibility. Later PMDA list entry also records a 2024 indication/dosage change for RET fusion gene-positive advanced or recurrent solid tumor. Confidence/conflicts: high for PMDA approval-list entry; no source conflict identified. Reimbursement not assessed.

Korea

  • amivantamab (Rybrevant) + lazertinib[35]ApprovedEGFR exon 19 deletion or exon 21 L858R substitution mutation; first-line treatment in adults with locally advanced or metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations. · This is an access/reimbursement finding, not proof of lack of MFDS approval. HIRA also notes coverage criteria may be set differently within MFDS-approved indications and may change during subsequent procedures. Confidence/conflicts: high for HIRA reimbursement-not-established result; MFDS approval status not verified in this finding. based on a company press release — confirm against the regulator label
  • atezolizumab (Tecentriq) + carboplatin + etoposide[36]Approvedfirst-line extensive-stage SCLC. · The fetched KBR article is an English secondary source; HIRA/MFDS primary confirmation remains a follow-up gap. Do not treat this as a current full reimbursement criteria extract. Confidence/conflicts: medium; no conflict identified, but primary HIRA/MFDS source should be fetched in a later pass.
  • durvalumab (Imfinzi)[37]MFDS-approved (Korea)limited-stage SCLC as monotherapy following platinum-based chemoradiotherapy. · This cell is based on an English KBR social-post mirror because the KBR article itself returned 403 on direct fetch and MFDS primary label was not fetched this cycle. Exact current label wording and reimbursement status need MFDS/HIRA confirmation. Confidence/conflicts: medium-low; no conflict identified, but MFDS primary confirmation is needed.
  • selpercatinib (Retevmo)[35]MFDS-approved (Korea)RET fusion-positive; locally advanced or metastatic RET fusion-positive NSCLC. · HIRA states reimbursement criteria were established; exact reimbursement criteria details and implementation timing may change during subsequent procedures. KBR is a secondary media source for MFDS approval history and should be superseded by MFDS primary label when fetched. Confidence/conflicts: high for HIRA reimbursement committee result; medium for MFDS approval details because primary MFDS source was not fetched. No conflict identified; KBR's uninsured statement predates the later HIRA result. based on a company press release — confirm against the regulator label
  • tarlatamab (Imdelltra)[38]MFDS-approved (Korea)DLL3-targeting bispecific; no biomarker test requirement stated in fetched sources; third-line ES-SCLC after at least two prior therapies including platinum-based chemotherapy. · KBR reports that few Korean patients were receiving Imdelltra and that reimbursement coverage had been filed with HIRA but was not yet established at the time of the May 2026 article. HMA-EMA catalogue describes a planned South Korea post-marketing observational study for patients prescribed tarlatamab according to approved South Korean indications. Confidence/conflicts: medium-high for Korean approval/access status as reported; no conflict identified. MFDS/HIRA primary documents remain preferred follow-up sources.

China

  • atezolizumab (Tecentriq) + carboplatin + etoposide[39]NMPA-approved (China)first-line extensive-stage SCLC. · NMPA primary page linked in the Frontiers article failed to fetch this cycle with a 412/error response, so this cell relies on Roche's NMPA-attributed release and a peer-reviewed article summarizing NMPA-approved first-line ES-SCLC ICI combinations. Confidence/conflicts: medium-high; no conflict identified. NMPA primary page was identified but not fetchable this cycle. A secondary/company source is present; the cited primary source is the regulator/HTA/official record. Availability/reimbursement outside the approving regulator not established.
  • durvalumab (Imfinzi) + etoposide + carboplatin or cisplatin[39]NMPA-approved (China)first-line adult extensive-stage SCLC. · NMPA primary page linked in the Frontiers article failed to fetch this cycle with a 412/error response. Reimbursement and current Chinese product label were not verified. Confidence/conflicts: medium-high; no conflict identified. NMPA primary page was identified but not fetchable this cycle. A secondary/company source is present; the cited primary source is the regulator/HTA/official record.
  • lazertinib (Leclaza/Lazcluze) + amivantamab (Rybrevant)[40]NMPA-approved (China)EGFR-mutant; source headline and context specify EGFR-mutant NSCLC and later text references approval in the EGFR-mutant NSCLC combination context; EGFR-mutant progressive or recurrent NSCLC, as stated by the Yuhan release; first-line common EGFR mutation indication requires NMPA label confirmation. · This is a company release, not an NMPA primary source. It does not provide complete label wording, reimbursement status, or exact EGFR variant list in the fetched lines. Confidence/conflicts: medium for NMPA-attributed approval; no conflict identified. Confidence limited by company-source wording and lack of NMPA primary label. A secondary/company source is present; the cited primary source is the regulator/HTA/official record.
  • lorlatinib (Lorbrena)[41]NMPA-approved (China)ALK-positive; ALK-positive advanced NSCLC. · BioWorld article preview is a secondary regulatory news source and requires subscription for full article; NMPA primary-source confirmation remains needed. Do not infer reimbursement or access beyond the approval report. Confidence/conflicts: medium for NMPA-attributed approval; no conflict identified. Confidence limited by secondary/paywalled source and lack of NMPA primary label.
  • selpercatinib (Retevmo)[42]NMPA-approved (China)RET fusion-positive; locally advanced or metastatic RET fusion-positive NSCLC. · This is a company release hosted by PRNewswire, not a fetched NMPA primary label. NMPA primary-source confirmation remains needed before treating this as regulator-primary. Confidence/conflicts: medium-high for NMPA-attributed approval; no conflict identified. Confidence limited because NMPA primary source was not fetched. A secondary/company source is present; the cited primary source is the regulator/HTA/official record. Availability/reimbursement outside the approving regulator not established.
  • serplulimab (Hansizhuang) + chemotherapy[43]NMPA-approved (China)first-line extensive-stage SCLC. · Henlius is the product sponsor/company source. NMPA primary page failed to fetch this cycle; the Chinese label and reimbursement status were not verified. Confidence/conflicts: medium-high; no conflict identified. NMPA primary page remains a follow-up gap.

Russia

  • chemoradiation therapy patterns and short-term outcomes; no investigational drug intervention listedClinical trial · NCT05887011[44]Standard option (per ClinicalTrials.gov)patients receiving at least one radiation-therapy dose under prescribed concurrent or sequential chemoradiation for definitive treatment of locally advanced LS-SCLC based on local multidisciplinary-team decision. · Study status is active, not recruiting. The record describes treatment-practice observation, not comparative efficacy or regulatory approval. Confidence/conflicts: high for registry status and study scope; no source conflict identified.

Thailand

  • Crizotinib, ceritinib, brigatinib, alectinib, lorlatinib[45]ApprovedALK rearrangement-positive; ALK-rearrangement-positive advanced NSCLC; reimbursement detail specifically notes first-line ceritinib and brigatinib under CSMBS/OCPA. · Access is scheme-specific and the article is not a live reimbursement schedule. Confirm current CSMBS/OCPA, SSS, UCS, Thai FDA, and hospital formulary status before reuse. Confidence/conflicts: Medium-high for expert-described Thailand access context; primary payer/regulator source-pending. No conflict found.
  • Crizotinib, entrectinib[45]Standard option (per Translational Lung Cancer Research / AME Publishing)ROS1 fusion-positive; ROS1-positive advanced NSCLC, with first-line crizotinib CSMBS coverage context. · The source describes expert recommendations and healthcare-scheme access, not a Thai FDA label. ROS1 testing availability is described as present in some hospitals, with broader testing limitations. Confidence/conflicts: Medium-high for expert-described Thailand access context; primary payer/regulator source-pending. No conflict found.
  • Erlotinib, gefitinib, afatinib, dacomitinib, osimertinib[45]Standard option (per Translational Lung Cancer Research / AME Publishing)EGFR sensitizing mutations and EGFR T790M after progression context; Advanced NSCLC with EGFR mutation; first-line sensitizing EGFR mutation context for erlotinib reimbursement; second-line EGFR T790M-positive advanced NSCLC context for osimertinib reimbursement in CSMBS. · This is a peer-reviewed Thai expert recommendation/access article, not a Thai FDA label or national formulary primary source. Reimbursement varies by scheme and may have changed after publication. Confidence/conflicts: Medium-high for Thailand access/reimbursement context; primary regulator/formulary confirmation remains source-pending. No conflict found.
  • Molecular biomarker testing pathway to guide targeted therapy and immunotherapy discussions[45]Standard option (per Translational Lung Cancer Research / AME Publishing)EGFR, ALK, PD-L1, with limited panel testing for EGFR, KRAS G12C, ROS1, BRAF, RET, NTRK, MET exon 14, HER2 after EGFR/ALK-negative results; Newly diagnosed or treatment-planning context for advanced NSCLC biomarker evaluation before selecting targeted or immune-checkpoint therapy. · This is a testing/access pathway, not a drug treatment. Local laboratory availability, accreditation, and reimbursement may vary by hospital and insurance scheme. Confidence/conflicts: High for expert recommendation language; payer and laboratory implementation details remain source-pending. No conflict found.
  • Pembrolizumab, atezolizumab, nivolumab, ipilimumab, durvalumab, tremelimumab[45]Standard option (per Translational Lung Cancer Research / AME Publishing)PD-L1 expression; high PD-L1 tumor proportion score context; First-line pembrolizumab reimbursement context for advanced NSCLC with high PD-L1 expression under CSMBS. · Source does not provide Thai FDA label text or current live payer criteria. Reimbursement is scheme-specific and the listed immunotherapies may have different labeled indications. Confidence/conflicts: Medium-high for Thailand expert-access context; primary payer/regulator source-pending. No conflict found.

Sources

  1. FDA approval notice · regulator approval notice
  2. EMA EPAR — Lazcluze · regulator EPAR / product page
  3. EMA EPAR — Lorviqua · regulator EPAR / product page
  4. NICE TA1122 · HTA appraisal / guideline
  5. NICE TA1103 · HTA appraisal / guideline
  6. NICE TA1042 · HTA appraisal / guideline
  7. PMDA — Lorbrena (lorlatinib) review report · PMDA regulator review report
  8. FDA — approval notice (durvalumab, limited-stage SCLC) · FDA regulator approval notice
  9. FDA — approval notice (atezolizumab, extensive-stage SCLC) · FDA regulator approval notice
  10. FDA — traditional approval notice (tarlatamab-dlle, ES-SCLC) · FDA regulator approval notice
  11. EMA EPAR — Imfinzi · EMA EPAR
  12. NICE TA1091 · NICE health technology appraisal
  13. PMDA — Imfinzi (durvalumab) review report · PMDA regulator review report
  14. PMDA — Tecentriq (atezolizumab) safety information / indications · PMDA regulator safety/indications document
  15. PMDA — Imdelltra (tarlatamab) safety information · PMDA regulator safety/precautions document
  16. National Cancer Institute — national cancer agency PDQ · national cancer agency PDQ
  17. American Society of Clinical Oncology (ASCO) — professional society FDA approval news · professional society FDA approval news
  18. U.S. Food and Drug Administration (FDA) — regulator approval notice · regulator approval notice
  19. U.S. Food and Drug Administration — regulator approval notice · regulator approval notice
  20. U.S. Food and Drug Administration — regulator approval notice · regulator approval notice
  21. U.S. Food and Drug Administration — regulator approval notice · regulator approval notice
  22. U.S. Food and Drug Administration — official drug label · official drug label
  23. European Medicines Agency (EMA) — regulator SmPC / product-information PDF · regulator SmPC / product-information PDF
  24. European Medicines Agency — regulator CHMP opinion news · regulator CHMP opinion news
  25. European Medicines Agency — regulator product page / EPAR · regulator product page / EPAR
  26. NICE via NCBI Bookshelf — health technology appraisal · health technology appraisal
  27. National Institute for Health and Care Excellence (NICE) — health technology appraisal / guideline · health technology appraisal / guideline
  28. National Institute for Health and Care Excellence (NICE) — technology appraisal guidance · technology appraisal guidance
  29. Cancer Research UK — national cancer charity treatment information · national cancer charity treatment information
  30. NHS — national health service treatment overview · national health service treatment overview
  31. electronic medicines compendium (emc) / AstraZeneca UK Limited — official drug label / SmPC · official drug label / SmPC
  32. National Institute for Health and Care Excellence (NICE) — health technology appraisal / guideline · health technology appraisal / guideline
  33. National Institute for Health and Care Excellence (NICE) — health technology appraisal / guideline · health technology appraisal / guideline
  34. Pharmaceuticals and Medical Devices Agency (PMDA) — regulator approved-drugs list · regulator approved-drugs list
  35. Health Insurance Review & Assessment Service (HIRA) — payer/reimbursement committee notice · payer/reimbursement committee notice
  36. Korea Biomedical Review — medical news / access reporting · medical news / access reporting
  37. Korea Biomedical Review via LinkedIn — medical news social-post mirror / regulatory approval reporting · medical news social-post mirror / regulatory approval reporting
  38. Korea Biomedical Review — medical news / regulatory approval reporting · medical news / regulatory approval reporting
  39. Frontiers in Immunology — peer-reviewed pharmacoeconomic analysis / approval-context summary · peer-reviewed pharmacoeconomic analysis / approval-context summary
  40. Yuhan USA — company approval news release · company approval news release
  41. BioWorld — regulatory news / secondary source · regulatory news / secondary source
  42. PRNewswire / Innovent and Eli Lilly release — company approval news release · company approval news release
  43. Shanghai Henlius Biotech — company regulatory news release · company regulatory news release
  44. ClinicalTrials.gov — clinical-trial registry / non-interventional observational study · clinical-trial registry / non-interventional observational study
  45. Translational Lung Cancer Research / AME Publishing — peer-reviewed expert recommendations · peer-reviewed expert recommendations

This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Some options shown have accelerated or conditional approval, which can be narrowed or withdrawn — reconfirm at the source. Last checked June 2026.

Beyond approved care

In clinical trials & emerging options

Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.

In clinical trials

  • amivantamab + lazertinibClinical trial · NCT04487080Clinical trialPhase III trial (NCT04487080)EGFR exon19del/L858R locally advanced or metastatic NSCLC, first-line (MARIPOSA) · Active, not recruiting; routine access varies by country. ClinicalTrials.gov — NCT04487080
  • savolitinib + osimertinibClinical trial · NCT05261399Clinical trialPhase III trial (NCT05261399)EGFR-mutant NSCLC with MET after progression on osimertinib (SAFFRON) · Active, not recruiting Phase 3; investigational combination. ClinicalTrials.gov — NCT05261399
  • neladalkib (NVL-655)Clinical trial · NCT06765109Clinical trialPhase III trial (NCT06765109)TKI-naive advanced ALK-positive NSCLC vs alectinib (ALKAZAR) · Recruiting Phase 3; investigational ALK inhibitor. ClinicalTrials.gov — NCT06765109
  • selpercatinib (LY3527723)Clinical trial · NCT04194944Clinical trialPhase III trial (NCT04194944)advanced/metastatic RET fusion-positive NSCLC, first-line vs chemo±pembrolizumab (LIBRETTO-431) · Active, not recruiting; trial setting, not a blanket approval. ClinicalTrials.gov — NCT04194944
  • obrixtamig (DLL3 bispecific) + atezolizumab/carboplatin/etoposideClinical trial · NCT07472517Clinical trialPhase III trial (NCT07472517)first-line extensive-stage SCLC (DAREON-Lung-1) · Recruiting Phase 3; investigational DLL3 bispecific. ClinicalTrials.gov — NCT07472517
  • etoposide plus cisplatin with thoracic radiation therapyClinical trialClinical trialPer NCI PDQUnited States · no molecular biomarker gating stated; stage and fitness drive treatment selection; fit patients with limited-stage SCLC receiving initial curative-intent treatment. · This is a U.S. national-cancer-agency treatment summary rather than a drug label. The page does not individualize cisplatin fitness, radiation technique, or center-specific schedule selection in this finding. Confidence/conflicts: High for the NCI PDQ limited-stage standard-of-care framing and the cited etoposide-cisplatin plus thoracic-radiation regimen. No source conflict identified in this cycle. National Cancer Institute — national cancer agency PDQ
  • tarlatamab (Imdylltra)Clinical trialClinical trialNot recommended (NICE)United Kingdom · ES-SCLC after 2 or more lines of treatment including platinum-based chemotherapy. · This is a negative NHS routine-use recommendation, not a statement that the medicine has no regulatory authorisation elsewhere. Existing NHS treatment started before the guidance may continue under prior funding arrangements as NICE describes. Confidence/conflicts: high for NICE non-recommendation; no conflict identified. National Institute for Health and Care Excellence (NICE) — health technology appraisal / guideline
  • lorlatinib (Lorviqua)Clinical trial · NCT05599412Clinical trialTrial only (registry)Korea · ALK-positive; metastatic ALK-positive NSCLC under routine clinical practice in Korea. · Registry record is a post-marketing surveillance study with Pfizer in Seoul listed as location. It does not specify HIRA reimbursement criteria or current MFDS label wording. Confidence/conflicts: high for existence of Korea PMS study and setting; reimbursement and regulator label details unverified. ClinicalTrials.gov — clinical-trial registry / post-marketing surveillance
  • Alectinib versus platinum-based chemotherapyClinical trial · NCT03456076Clinical trialTrial only (NCT03456076)Russia · ALK-positive; Adjuvant treatment after complete resection of ALK-positive stage IB tumors at least 4 cm through stage IIIA NSCLC. · Trial geography does not establish local adjuvant approval or reimbursement for alectinib in Russia or Thailand. Confidence/conflicts: High for registry status and country list; local routine access source-pending. No conflict found. ClinicalTrials.gov — clinical-trial registry
  • Amivantamab plus lazertinib versus osimertinib or lazertinibClinical trial · NCT04487080Clinical trialTrial only (NCT04487080)Russia · EGFR exon 19 deletion or exon 21 L858R substitution; Newly diagnosed, treatment-naive locally advanced or metastatic NSCLC not amenable to curative therapy, with EGFR exon 19 deletion or L858R substitution. · Active-not-recruiting registry status does not establish new enrollment, approval, reimbursement, or routine availability in Russia or Thailand. Confidence/conflicts: High for registry status and country list; routine access source-pending. No conflict found. ClinicalTrials.gov — clinical-trial registry
  • Ceralasertib plus durvalumabClinical trial · NCT05941897Clinical trialTrial only (NCT05941897)Russia · EGFR and ALK wild-type; without actionable genomic alterations per registry wording; Second- or third-line context after disease progression on or after prior anti-PD-(L)1 therapy and platinum doublet chemotherapy for locally advanced or metastatic NSCLC. · Trial listing only; it does not establish routine Russian access, approval, or reimbursement for ceralasertib plus durvalumab. Confidence/conflicts: High for registry status and Russia-only geography; no conflict found. ClinicalTrials.gov — clinical-trial registry
  • Lazertinib (YH25448) versus gefitinibClinical trial · NCT04248829Clinical trialTrial only (NCT04248829)Russia · EGFR exon 19 deletion or exon 21 L858R sensitizing mutation; First-line treatment-naive locally advanced or metastatic NSCLC with EGFR exon 19 deletion or L858R mutation. · Completed trial geography does not establish current Russian or Thai regulatory approval, reimbursement, or routine access for lazertinib. Confidence/conflicts: High for registry status and country list; routine access source-pending. No conflict found. ClinicalTrials.gov — clinical-trial registry
  • Mevrometostat (PF-06821497)Clinical trial · NCT03460977Clinical trialTrial only (NCT03460977)Russia · Relapsed/refractory SCLC historical/closed enrollment cohorts within the study; current open Part 3 is described for castration-resistant prostate cancer, not SCLC. · This is not a current SCLC enrollment option based on the fetched summary. It should be retained as historical Russia SCLC investigational context only unless the registry changes. Confidence/conflicts: High for registry status and closed SCLC cohort caveat; no conflict found. ClinicalTrials.gov — clinical-trial registry
  • chemo-radiation therapy pattern/outcomes studyClinical trial · NCT05887011Clinical trialTrial only (registry)Russia · unresectable NSCLC and SCLC; chemoradiation patterns in routine practice. · Overall status is ACTIVE_NOT_RECRUITING and last update was 2026-05-27. This is an observational/practice-pattern study rather than an approval or efficacy trial for a specific product. Confidence/conflicts: high for registry record and Russian sites; no source conflict identified. It is not a regulatory approval source. ClinicalTrials.gov — clinical-trial registry
  • dinutuximab + irinotecan versus irinotecan; topotecan listed in interventionsClinical trial · NCT03098030Clinical trialTrial only (NCT03098030)Russia · second-line treatment of relapsed or refractory SCLC after relapse/progression during or after first-line platinum-based therapy; no curative therapy available in eligibility language. · Study status is completed. Registry participation does not imply current access, approval, or eligibility for any individual patient. Confidence/conflicts: high for trial participation/status; no source conflict identified. ClinicalTrials.gov — clinical-trial registry
  • durvalumab +/- tremelimumab with platinum-based chemotherapy (carboplatin or cisplatin plus etoposide)Clinical trial · NCT03043872Clinical trialTrial only (NCT03043872)Russia · first-line treatment in untreated extensive-disease SCLC suitable for platinum-based chemotherapy. · Study status is active, not recruiting. Registry participation does not imply current enrollment access, approval, or individual eligibility. Confidence/conflicts: high for trial participation/status; no source conflict identified. ClinicalTrials.gov — clinical-trial registry
  • durvalumab plus oleclumab after chemoradiationClinical trial · NCT06606847Clinical trialTrial only (registry)Russia · following chemoradiation in locally advanced unresectable NSCLC. · Overall status is ACTIVE_NOT_RECRUITING and last update was 2026-05-15. The registry record does not establish access outside the study. Confidence/conflicts: high for trial existence and Russian sites; no source conflict identified. Russian regulatory status unverified. ClinicalTrials.gov — clinical-trial registry
  • selpercatinib (LY3527723) with comparator regimens including platinum/pemetrexed/pembrolizumab in the studyClinical trial · NCT04194944Clinical trialTrial only (registry)Russia · RET fusion-positive; advanced or metastatic RET fusion-positive NSCLC. · Overall status is ACTIVE_NOT_RECRUITING and last update was 2025-10-21. Russian sites include Ufa, Kaluga, Murmansk, Samara, and Saint Petersburg in the fetched results. Confidence/conflicts: high for trial existence and Russian sites; no source conflict identified. Russian regulatory status unverified. ClinicalTrials.gov — clinical-trial registry
  • JIN-A02Clinical trial · NCT05394831Clinical trialTrial only (NCT05394831)Thailand · EGFR C797S or T790M and other EGFR-mutant cohort definitions in the registry; EGFR-mutant advanced or metastatic NSCLC after standard anticancer therapy, including approved EGFR-TKI therapy and/or up to one platinum-based chemotherapy; registry Part A/B includes C797S or T790M mutation-positive disease. · Trial access is investigational and the Thailand site status is not-yet-recruiting in the fetched record; no routine approval is established. Confidence/conflicts: High for registry status and site-state detail; no conflict found. ClinicalTrials.gov — clinical-trial registry
  • Neladalkib (NVL-655) compared with alectinibClinical trial · NCT06765109Clinical trialTrial only (NCT06765109)Thailand · ALK-positive; Treatment-naive locally advanced or metastatic ALK-positive NSCLC; prior ALK TKI is not allowed by registry criteria. · Investigational trial listing only; it does not establish Thailand routine access or approval for neladalkib. Confidence/conflicts: High for registry status and country list; no conflict found. ClinicalTrials.gov — clinical-trial registry
  • Obrixtamig plus atezolizumab, carboplatin, and etoposide versus atezolizumab, carboplatin, and etoposideClinical trial · NCT07472517Clinical trialTrial only (NCT07472517)Thailand · DLL3 expression status assessed by investigational VENTANA DLL3 test before randomisation; First-line ES-SCLC without previous systemic anticancer treatment for ES-SCLC, with limited-stage prior systemic therapy allowed only if completed more than six months before ES-SCLC diagnosis. · Investigational trial listing only; it does not establish Thai FDA approval or routine access for obrixtamig. The standard-treatment comparator arms are trial context, not a complete Thailand access statement. Confidence/conflicts: High for registry status and country list; no conflict found. ClinicalTrials.gov — clinical-trial registry
  • dinutuximab + irinotecan versus irinotecan; topotecan listed in interventionsClinical trial · NCT03098030Clinical trialTrial only (NCT03098030)Thailand · second-line treatment of relapsed or refractory SCLC after relapse/progression during or after first-line platinum-based therapy; no curative therapy available in eligibility language. · Study status is completed. Registry participation does not imply current access, approval, or eligibility for any individual patient. Confidence/conflicts: high for trial participation/status; no source conflict identified. ClinicalTrials.gov — clinical-trial registry
  • lazertinib (YH25448) versus gefitinibClinical trial · NCT04248829Clinical trialTrial only (registry)Thailand · EGFR mutation-positive; first-line EGFR mutation-positive locally advanced or metastatic NSCLC. · Overall status is COMPLETED and last update was 2026-05-28. Thai sites include Ramathibodi Hospital, Siriraj Hospital, Chiang Mai University, Prince of Songkla University, and Srinagarind Hospital/Khon Kaen University. Confidence/conflicts: high for trial existence and Thai sites; no source conflict identified. Thai regulatory status unverified. ClinicalTrials.gov — clinical-trial registry
  • rilvegostomig or pembrolizumab plus platinum/pemetrexed chemotherapyClinical trial · NCT06627647Clinical trialTrial only (registry)Thailand · first-line metastatic non-squamous NSCLC. · Overall status is RECRUITING and last update was 2026-05-22. The registry record does not establish routine access outside the study. Confidence/conflicts: high for trial existence and Thai sites; no source conflict identified. Thai regulatory status unverified. ClinicalTrials.gov — clinical-trial registry
  • savolitinib plus osimertinib versus platinum-based doublet chemotherapyClinical trial · NCT05261399Clinical trialTrial only (registry)Thailand · EGFR-mutant disease implied by prior osimertinib; MET-driven rationale not asserted beyond intervention name; after progression on osimertinib treatment. · Overall status is ACTIVE_NOT_RECRUITING and last update was 2026-04-06. The registry record does not establish access outside the trial. Confidence/conflicts: high for trial existence and Thai sites; no source conflict identified. Thai regulatory status unverified. ClinicalTrials.gov — clinical-trial registry

A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked June 2026.

What this page does

Maps options by country

It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.

What it does not do

Does not choose treatment

It does not rank treatments, recommend a choice, or decide clinical fit.

Where it comes from

Built on trusted sources

Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.

Why this condition is included

  • Families often need to separate non-small cell lung cancer, small cell lung cancer, stage, and biomarker testing.
  • The first MatchMedi version should help users gather the right report details before a lung oncology visit.
  • Each option links to its regulator, HTA, or guideline source, with country-specific access noted where known.

Information to gather before the next visit

  • Is the diagnosis non-small cell lung cancer, small cell lung cancer, or another subtype?
  • What stage is documented, and is the cancer resectable?
  • Which biomarker tests were ordered or completed?
  • Did the oncologist mention immunotherapy, targeted therapy, chemotherapy, radiation, surgery, or trials?

Trial-search terms to discuss

non-small cell lung cancer biomarker clinical triallung cancer targeted therapy clinical trial